Bailard’s Aerie Pharmaceuticals AERI Stock Holding History

Bailard’s Portfolio AERI Stock Details AERI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6,500	Closed	-$309K	–	614
2019 Q1	$309K	Hold	6,500	–	–	0.02%	417
2018 Q4	$235K	Hold	6,500	–	–	0.02%	453
2018 Q3	$400K	Hold	6,500	–	–	0.02%	422
2018 Q2	$439K	Sell	6,500 -16,150	-71%	-$904K	0.03%	393
2018 Q1	$1.23M	Hold	22,650	–	–	0.08%	202
2017 Q4	$1.35M	Buy	22,650 +5,400	+31%	+$327K	0.09%	207
2017 Q3	$838K	Sell	17,250 -17,250	-50%	-$941K	0.06%	179
2017 Q2	$1.81M	Sell	34,500 -16,000	-32%	-$745K	0.15%	137
2017 Q1	$2.29M	Sell	50,500 -32,500	-39%	-$1.45M	0.19%	117
2016 Q4	$3.14M	Hold	83,000	–	–	0.29%	91
2016 Q3	$3.13M	Sell	83,000 -30,000	-27%	-$662K	0.29%	87
2016 Q2	$1.99M	Hold	113,000	–	–	0.24%	106
2016 Q1	$1.37M	Buy	113,000 +93,000	+465%	+$1.47M	0.19%	83
2015 Q4	$487K	Sell	20,000 -13,000	-39%	-$303K	0.21%	141
2015 Q3	$585K	Buy	+33,000	New	+$598K	0.09%	128

Other funds holding AERI

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Bailard's AERI Position: Q2 2019 in Review

Bailard sold out of Aerie Pharmaceuticals (AERI) in Q2 2019, closing a stake of 6,500 shares — an estimated $309K sold.

Bailard first reported a position in AERI in Q3 2015 and held it in 15 quarters. The position peaked at $3.14M in Q4 2016. 167 funds tracked by Wall St. Rank hold AERI as of Q2 2019.

Bailard reported no remaining Aerie Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Bailard sold 6,500 Aerie Pharmaceuticals shares in Q2 2019, an estimated $309K.
Bailard first reported a position in Aerie Pharmaceuticals in Q3 2015 and held it in 15 quarters.
Bailard's Aerie Pharmaceuticals position peaked at $3.14M in Q4 2016.
167 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2019.

Based on Bailard's 13F filing for Q2 2019, filed 26 Jul 2019.